APA

Meyers F. J., O' Donnell R. T., . (20010322). Correspondence re: G. C. de Gast et al., Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma. Clin. Cancer Res., 6: 1267-1272, 2000. : Clinical cancer research : an official journal of the American Association for Cancer Research.

Chicago

Meyers F J, O' Donnell R T, . 20010322. Correspondence re: G. C. de Gast et al., Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma. Clin. Cancer Res., 6: 1267-1272, 2000. : Clinical cancer research : an official journal of the American Association for Cancer Research.

Harvard

Meyers F. J., O' Donnell R. T., . (20010322). Correspondence re: G. C. de Gast et al., Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma. Clin. Cancer Res., 6: 1267-1272, 2000. : Clinical cancer research : an official journal of the American Association for Cancer Research.

MLA

Meyers F J, O' Donnell R T, . Correspondence re: G. C. de Gast et al., Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma. Clin. Cancer Res., 6: 1267-1272, 2000. : Clinical cancer research : an official journal of the American Association for Cancer Research. 20010322.